Vitae Industries

Vitae Industries is a Providence, Rhode Island-based company founded by Jeanine Sinanan-Singh (CEO) and Daniel DeCiccio (CTO), focused on developing automated hardware for pharmaceutical compounding. The company participated in the Techstars New York City accelerator program during its early stage and subsequently raised a seed financing round of approximately $1.8 million led by Slater Fund. Vitae Industries is headquartered at 1 Richmond Square in Providence, Rhode Island, and has drawn attention from the local business community, with Sinanan-Singh recognized among notable Rhode Island entrepreneurs to watch in 2020.

The company's flagship product is the AutoCompounder, a device that automates the pharmaceutical compounding workflow and allows pharmacists to produce personalized medication dosage forms with significantly reduced manual effort. The system is designed to lower the technical complexity and labor burden traditionally associated with in-house drug compounding, enabling independent pharmacies to offer customized medications at competitive cost and with greater batch consistency. Vitae Industries also produces physical accessories intended for use alongside the AutoCompounder within pharmacy compounding environments. The company's commercial focus is on improving the economic viability of independent pharmacy operations, helping smaller operators compete with large chain drugstores that benefit from centralized, high-volume compounding infrastructure and economies of scale.

Vitae Industries addresses the growing clinical demand for personalized medicine by making compounding technology more accessible to community pharmacists across the United States. The AutoCompounder serves patients who require customized medication formulations due to specific dosage requirements, ingredient allergies, or needs for non-standard delivery forms unavailable in commercially manufactured pharmaceutical products. The device is designed to produce consistent results across repeated compounding runs, reducing the variability that can arise from manual preparation methods. By reducing the barrier to in-house compounding, the company aims to expand patient access to individualized therapies while enabling independent pharmacy operators to retain revenue streams that might otherwise flow to specialized compounding pharmacies or larger retail chains.